DCTH Stock Price, Delcath Systems, Inc. Quote, Chart

Market Summary

USD7.55+0.59

Delayed

8.48%

DCTH Stock Price

View Fullscreen

DCTH RSI Chart

DCTH Valuation

Market Cap

209.8M

Price/Earnings (Trailing)

-4.21

Price/Sales (Trailing)

45.54

Price/Free Cashflow

-5.72

DCTH Price/Sales (Trailing)

DCTH Profitability

Operating Margin

70.54%

Return on Equity

-340.55%

Return on Assets

-137.92%

Free Cashflow Yield

-17.49%

DCTH Fundamentals

DCTH Revenue

Revenue (TTM)

4.6M

Rev. Growth (Yr)

-52.1%

Rev. Growth (Qtr)

-12.32%

DCTH Earnings

Earnings (TTM)

-49.8M

Earnings Growth (Yr)

-23.46%

Earnings Growth (Qtr)

0.22%

Breaking Down DCTH Revenue

Last 7 days

32.2%

Last 30 days

68.9%

Last 90 days

71.6%

Trailing 12 Months

8.6%

How does DCTH drawdown profile look like?

DCTH Financial Health

Current Ratio

2.52

DCTH Investor Care

Shares Dilution (1Y)

176.57%

Diluted EPS (TTM)

-2.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.6M	0	0	0
2023	2.9M	2.6M	2.2M	2.1M
2022	3.2M	3.2M	3.3M	2.7M
2021	0	0	0	3.6M
2018	2.7M	2.9M	3.1M	0
2017	2.4M	2.4M	2.7M	2.7M
2016	1.7M	1.7M	1.8M	2.0M
2015	1.2M	1.4M	1.6M	1.7M
2014	720.0K	971.0K	1.1M	1.1M
2013	457.3K	568.5K	679.8K	791.0K
2012	0	0	0	346.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Delcath Systems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 19, 2024	muir kevin	acquired	50,000	3.72	13,441	gm interventional oncology
Mar 19, 2024	hoffman david l.	acquired	74,998	3.72	20,161	gen'l counsel, cco & secy
Mar 19, 2024	michel gerard j	acquired	150,002	3.72	40,323	chief executive officer
Mar 19, 2024	salamon steven a j	bought	100,001	3.72	26,882	-
Mar 19, 2024	vukovic vojo	acquired	100,001	3.72	26,882	chief medical officer
Mar 19, 2024	pennell sandra	acquired	99,997	3.72	26,881	svp of finance, pfo and pao
Mar 19, 2024	aharon gil	bought	100,001	3.72	26,882	-
Dec 12, 2023	vukovic vojo	bought	120,000	3.00	40,000	chief medical officer
Dec 08, 2023	michel gerard j	bought	99,960	2.94	34,000	chief executive officer
Nov 17, 2023	rosalind advisors, inc.	bought	240,410	2.4041	100,000	-

Which funds bought or sold DCTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	LEVIN CAPITAL STRATEGIES, L.P.	added	12.18	58,362	262,202	0.03%
May 16, 2024	WealthPlan Investment Management, LLC	unchanged	-	10,640	83,203	0.01%
May 16, 2024	JANE STREET GROUP, LLC	new	-	111,762	111,762	-%
May 15, 2024	Engineers Gate Manager LP	new	-	53,863	53,863	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-24.96	-33,214	204,676	-%
May 15, 2024	Royal Bank of Canada	added	5,203	17,000	17,000	-%
May 15, 2024	BVF INC/IL	added	23.14	1,673,080	5,733,860	0.16%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-40.32	-28,512	61,814	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	21.39	49,322	175,183	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-33.55	-129,177	413,392	-%

Are Funds Buying or Selling DCTH?

Are funds buying DCTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DCTH

No. of Funds

Unveiling Delcath Systems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	rosalind advisors, inc.	9.9%	1,151,907	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	6.2%	1,433,024	SC 13G/A
Feb 13, 2024	vivo opportunity fund holdings, l.p.	9.99%	2,708,579	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0.9%	208,333	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	0.0%	0	SC 13G/A
Jan 09, 2024	hirschman orin	6.8%	1,539,638	SC 13G
Nov 28, 2023	rosalind advisors, inc.	9.9%	1,098,143	SC 13D/A
Aug 16, 2023	soleus capital master fund, l.p.	5.3%	806,420	SC 13G
Jun 26, 2023	stonepine capital management, llc	8.7%	976,008	SC 13G
Jun 22, 2023	biotechnology value fund l p	6.5%	1,012,121	SC 13G

Recent SEC filings of Delcath Systems, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13D/A	13D - Major Acquisition
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4/A	Insider Trading
May 16, 2024	4/A	Insider Trading
May 16, 2024	4/A	Insider Trading
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 09, 2024	424B3	Prospectus Filed

Peers (Alternatives to Delcath Systems, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Delcath Systems, Inc. News

Latest updates

Delcath Systems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1
Revenue	482.4%	3,139	539	434	495	597	639	906	797	378	1,171	824	858	702	704	684	584	743	676	435	511	370
Cost Of Revenue	428.1%	903	171	133	150	181	238	235	180	33.00	130	233	220	-	-	-	-	-	-	-	-	-
Gross Profit	507.6%	2,236	368	301	345	416	401	671	617	345	1,979	591	638	-	-	-	-	-	-	-	-	-
Operating Expenses	7.2%	12,514	11,672	10,857	8,342	8,741	8,256	8,844	10,103	8,685	6,636	6,385	6,730	-	-	-	-	-	-	-	-	-
S&GA Expenses	26.6%	8,814	6,963	6,195	4,787	4,165	3,825	4,779	4,497	4,204	3,017	2,279	2,641	-	-	-	-	-	-	-	-	-
R&D Expenses	-21.4%	3,700	4,709	4,662	3,555	4,576	4,431	4,065	5,606	4,481	3,619	4,106	4,089	-	-	-	-	-	-	-	-	-
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-7.58*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-25.8%	250	337	335	296	491	536	495	431	411	421	-	-	-	1,379	5,042	6,916	-	7,744	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-	-	-	-14.61*	-	-	-	-	-	-	-	-	-	-
Net Income	0.2%	-11,111	-11,136	-20,340	-7,202	-9,000	-8,472	-8,877	-10,159	-9,000	-5,347	-8,880	-6,658	-	-	-	-	-	-	-	-	-
Net Income Margin	53.2%	-10.81*	-23.09*	-20.80*	-12.73*	-12.42*	-13.42*	-10.27*	-9.98*	-8.64*	-7.21*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-16.4%	-9,597	-8,246	-9,172	-9,676	-4,264	-7,359	-5,247	-6,089	-6,464	-6,028	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.5%	36.00	39.00	48.00	21.00	31.00	18.00	20.00	21.00	27.00	33.00	34.00	25.00	32.00	35.00	17.00	20.00	10.00	14.00	19.00	6.00	6.00
Current Assets	-9.5%	34.00	37.00	46.00	19.00	29.00	16.00	18.00	19.00	25.00	31.00	32.00	23.00	30.00	32.00	14.00	19.00	8.00	13.00	17.00	3.00	3.00
Cash Equivalents	-7.0%	12.00	13.00	40.00	15.00	24.00	8.00	10.00	10.00	16.00	23.00	25.00	19.00	27.00	29.00	11.00	16.00	5.00	10.00	15.00	0.00	0.00
Inventory	9.4%	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-1.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-5.9%	21.00	23.00	23.00	21.00	25.00	24.00	25.00	24.00	22.00	21.00	23.00	10.00	12.00	13.00	13.00	13.00	18.00	21.00	38.00	35.00	30.00
Current Liabilities	-18.9%	13.00	16.00	14.00	11.00	13.00	15.00	14.00	12.00	9.00	6.00	5.00	6.00	10.00	10.00	11.00	8.00	13.00	16.00	32.00	31.00	25.00
Shareholder's Equity	-7.3%	15.00	16.00	25.00	-	-13.08	-5.86	-	-	5.00	12.00	12.00	15.00	20.00	22.00	3.00	8.00	-	-	-	-	-
Retained Earnings	-2.2%	-516	-505	-494	-473	-466	-457	-447	-438	-429	-420	-415	-408	-402	-395	-388	-383	-379	-371	-383	-357	-351
Additional Paid-In Capital	1.9%	530	521	519	473	453	452	442	436	434	433	427	424	422	417	392	391	371	365	365	328	328
Accumulated Depreciation	0.4%	5.00	5.00	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	7.9%	25.00	23.00	20.00	15.00	10.00	10.00	9.00	8.00	8.00	8.00	8.00	7.00	6.00	6.00	-	-	-	-	-	-	-
Float	-	-	-	-	82.00	-	-	-	31,948	-	-	-	87.00	-	-	-	34.00	-	-	-	2.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-16.5%	-9,584	-8,227	-9,173	-9,636	-4,264	-7,359	-5,179	-6,037	-6,375	-6,029	-4,906	-7,102	-4,567	-5,040	-4,746	-7,853	-5,229	-5,367	-12,360	-3,192	-2,770
Cashflow From Investing	123.7%	4,660	-19,670	1.00	-40.00	-	-	-68.00	-52.00	-89.00	1.00	-56.00	-79.00	-9.00	-74.00	-487	-41.00	-180	-22.00	-	-	-2.00
Cashflow From Financing	402000.0%	4,021	1.00	35,076	7.00	16,694	5,247	4,896	-	-	3,927	14,502	17.00	2,376	22,883	223	19,366	-117	-25.00	26,461	3,319	550
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,160

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DCTH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product revenue	$ 3,139	$ 597
Other revenue	0	0
Total revenues	3,139	597
Cost of goods sold	(903)	(181)
Gross profit	2,236	416
Operating expenses:
Research and development expenses	3,700	4,576
Selling, general and administrative expenses	8,814	4,165
Total operating expenses	12,514	8,741
Operating loss	(10,278)	(8,325)
Change in fair value of warrant liability	(612)	0
Interest expense, net	(199)	(688)
Other (expense) income	(22)	13
Net loss	(11,111)	(9,000)
Other comprehensive (loss) income:
Unrealized gain on investments	8	0
Foreign currency translation adjustments	14	19
Total comprehensive loss	$ (11,089)	$ (8,981)
Common share data:
Basic loss per common share (in dollars per share)	$ (0.45)	$ (0.77)
Diluted loss per common share (in dollars per share)	$ (0.45)	$ (0.77)
Weighted average number of basic shares outstanding (in shares)	24,887,180	11,622,384
Weighted average number of diluted shares outstanding (in shares)	24,887,180	11,622,384

DCTH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 11,760	$ 12,646
Restricted cash	50	50
Short-term investments	15,360	19,808
Accounts receivable, net	1,564	241
Inventory	3,634	3,322
Prepaid expenses and other current assets	1,278	1,091
Total current assets	33,646	37,158
Property, plant and equipment, net	1,336	1,352
Right-of-use assets	1,117	103
Total assets	36,099	38,613
Current liabilities
Accounts payable	1,487	1,012
Accrued expenses	4,395	5,249
Lease liabilities, current	102	37
Loan payable	2,408	5,239
Convertible notes payable	4,949	4,911
Total current liabilities	13,341	16,448
Warrant liability	6,160	5,548
Lease Liabilities, non-current	1,016	0
Other liabilities, non-current	962	840
Total liabilities	21,479	22,836
Commitments and contingencies (see Note 15)
Stockholders’ equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 16,809 and 24,819 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 25,439,319 shares and 22,761,554 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	254	228
Additional paid-in capital	530,482	520,576
Accumulated deficit	(516,273)	(505,162)
Accumulated other comprehensive loss	157	135
Total stockholders’ equity	14,620	15,777
Total liabilities and stockholders’ equity	$ 36,099	$ 38,613

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

CEO	Mr. Gerard J. Michel MBA, MS
WEBSITE	delcath.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	52

Delcath Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Delcath Systems, Inc.? What does DCTH stand for in stocks?

DCTH is the stock ticker symbol of Delcath Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Delcath Systems, Inc. (DCTH)?

As of Fri May 17 2024, market cap of Delcath Systems, Inc. is 209.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCTH stock?

You can check DCTH's fair value in chart for subscribers.

What is the fair value of DCTH stock?

You can check DCTH's fair value in chart for subscribers. The fair value of Delcath Systems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Delcath Systems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DCTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Delcath Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether DCTH is over valued or under valued. Whether Delcath Systems, Inc. is cheap or expensive depends on the assumptions which impact Delcath Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCTH.

What is Delcath Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DCTH's PE ratio (Price to Earnings) is -4.21 and Price to Sales (PS) ratio is 45.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCTH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Delcath Systems, Inc.'s stock?

In the past 10 years, Delcath Systems, Inc. has provided -0.806 (multiply by 100 for percentage) rate of return.